Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

The case for Eli Lilly. To be fair, while Novo Nordisk has the lead in the GLP-1 arena, I have to note that Lilly's Mounjaro and Zepbound have not been on the market nearly as long as its ...

Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong ...

Eli Lilly and Novo Nordisk have competed for decades. They're both leaders in the areas of insulin and broader diabetes drugs, where they've made significant breakthroughs and fought for market share.

Let's take a look at four other pharmaceutical companies and explore how each could represent a lucrative investment opportunity as they look to catch up with incumbents Eli Lilly and Novo Nordisk. 1.

Novo Nordisk and Eli Lilly reported booming sales Thursday from the new generation of diabetes and weight-loss drugs they’ve pioneered, as both drugmakers continue to scramble to keep up with ...

Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are the top two companies in the weight loss market right now. They are both raking in billions in revenue from their glucagon-like peptide-1 ...

Eli Lilly is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk being its biggest challenger. Over the past six months, Eli Lilly has earned significant wins ...